Nefazodone

Nefazodone — once Serzone — was a popular antidepressant in the late 1990s. It is rarely prescribed now, and the story of why is worth knowing as a case study in how a real but rare adverse effect can reshape a drug's role.

The mechanism is similar to trazodone — a SARI, blocking 5-HT2A receptors strongly and inhibiting SERT weakly. Less alpha-1 antagonism than trazodone, so less orthostasis. The clinical profile was attractive: useful sleep effect, lower sexual dysfunction than SSRIs, useful for depression with anxiety or insomnia.

Then the hepatotoxicity reports accumulated. Rare but real cases of severe liver failure, including fatal cases and cases requiring liver transplant, were attributed to nefazodone. The estimated rate was approximately one in 250,000 to 300,000 patient-years — uncommon, but not vanishingly so. The brand product Serzone was withdrawn from many markets, including most of Europe and several other countries. In the United States, the brand was withdrawn voluntarily; the generic remained available but use plummeted.

A class-effect comparison gives the context. Most antidepressants have some hepatic signal — duloxetine, valproate, even SSRIs occasionally — but nefazodone's signal was high enough and the alternatives plentiful enough that the cost-benefit calculation shifted decisively against its routine use.

Today, nefazodone has a narrow niche. The patient who has responded well to nefazodone historically without liver problems may reasonably continue. The clinician with a specific situation — say, a patient with PTSD where there is some literature suggesting nefazodone benefit and alternatives have failed — might still consider it. For new starts, the calculation almost always favors a different agent.

If you do encounter nefazodone in a chart, the relevant questions are: was the patient warned about the hepatotoxicity risk? Are LFTs being monitored? Is there evidence of hepatic injury? Are there safer alternatives that could be tried?

Side effects beyond hepatotoxicity follow the SARI pattern. Sedation is significant — less than trazodone but real. Dizziness, dry mouth, asthenia. The sexual dysfunction rate is meaningfully lower than SSRIs, which was the original clinical appeal. Drug interactions are substantial — nefazodone is a potent CYP3A4 inhibitor and interacts with many co-medications.

Dosing is BID or TID, starting at 100 milligrams BID and titrating to 200-300 milligrams BID. The frequent dosing is itself an adherence challenge.

Nefazodone's story is a useful reminder. A drug that works well for most patients can become a wrong choice when a rare but severe adverse effect emerges and equivalent safer alternatives exist. The threshold for "rare enough to ignore" depends on what else is available.